Related Experiment Video
Updated: Aug 16, 2025
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
MTAP loss: a possible therapeutic approach for glioblastoma
C Pawan K Patro1,2, Nupur Biswas3, Sandeep C Pingle1
1CureScience, 5820 Oberlin Dr, 202, San Diego, CA, 92121, USA.
Abstract:
Glioblastoma is the most lethal form of brain tumor with a recurrence rate of almost 90% and a survival time of only 15 months post-diagnosis. It is a highly heterogeneous, aggressive, and extensively studied tumor. Multiple studies have proposed therapeutic approaches to mitigate or improve the survival for patients with glioblastoma. In this article, we review the loss of the 5'-methylthioadenosine phosphorylase (MTAP) gene as a potential therapeutic approach for treating glioblastoma. MTAP encodes a metabolic enzyme required for the metabolism of polyamines and purines leading to DNA synthesis. Multiple studies have explored the loss of this gene and have shown its relevance as a therapeutic approach to glioblastoma tumor mitigation; however, other studies show that the loss of MTAP does not have a major impact on the course of the disease. This article reviews the contrasting findings of MTAP loss with regard to mitigating the effects of glioblastoma, and also focuses on multiple aspects of MTAP loss in glioblastoma by providing insights into the known findings and some of the unexplored areas of this field where new approaches can be imagined for novel glioblastoma therapeutics.
Insights
Loss of the 5'-methylthioadenosine phosphorylase (MTAP) gene is explored as a glioblastoma treatment. This review examines conflicting research on MTAP's role in glioblastoma progression and therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Glioblastoma is an aggressive brain tumor with a high recurrence rate and poor prognosis.
- The 5 methylthioadenosine phosphorylase (MTAP) gene plays a role in purine and polyamine metabolism, crucial for DNA synthesis.
- MTAP gene loss is frequently observed in glioblastoma, suggesting its potential as a therapeutic target.
Purpose of the Study:
- To review the current literature on the significance of MTAP gene loss in glioblastoma.
- To analyze contrasting findings regarding MTAP loss as a therapeutic strategy for glioblastoma.
- To identify unexplored areas and potential novel therapeutic approaches related to MTAP loss in glioblastoma.
Main Methods:
- Literature review of studies investigating MTAP gene status in glioblastoma.
- Analysis of research examining the functional impact of MTAP loss on glioblastoma biology.
- Synthesis of findings to highlight discrepancies and future research directions.
Main Results:
- Studies show conflicting results on whether MTAP loss impacts glioblastoma progression or serves as a viable therapeutic target.
- Some research indicates MTAP loss is relevant for glioblastoma mitigation, while others suggest minimal impact.
- The precise role of MTAP in glioblastoma heterogeneity and treatment response remains incompletely understood.
Conclusions:
- The therapeutic potential of targeting MTAP loss in glioblastoma requires further investigation due to conflicting evidence.
- Understanding the complex role of MTAP in glioblastoma is crucial for developing effective novel therapeutics.
- Future research should focus on elucidating the mechanisms underlying MTAP loss and its implications for glioblastoma treatment strategies.
